Monitor for whether this is part of a pre-arranged 10b5-1 trading plan — common for executives to sell after option vesting. Given the coordinated timing and lack of purchases, this reflects routine portfolio management, not a negative signal. However, sustained selling in future periods could indicate weakening confidence.
Price Chart
Executive Summary
Seven executives at Teva Pharmaceutical exercised stock options and sold shares in the open market on March 5, 2026, generating over $2.7M in aggregate proceeds. The transactions were primarily driven by option exercises followed by sales, with CEO Francis Richard D and multiple EVPs selling significant portions of their exercised shares. This is a routine insider disposition pattern, not indicative of distress or strong conviction.
Key Financial Metrics
Key Facts
- CEO Francis Richard D sold 20,025 shares for $634,160 after exercising 42,452 options (non-cash).
- Multiple EVPs (Fox, Daniell, Hughes, Shields, Jover, Savage) conducted similar exercise-and-sell transactions on the same day.
- Total open-market sales in the cluster: $2,766,108 across 7 insiders.
- All derivative exercises were at $0 cost, indicating pre-granted stock options.
- No open-market purchases observed; all transactions were sales or non-cash exercises.
Financial Impact
$2.77M in insider sales over one day
Risk Factors
- Perception of insider pessimism if selling continues beyond planned schedules.
- Potential dilution from exercised options, though offset by typical treasury share practices.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-TEVA-1773087521251 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.26 (+8.02%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.26 (+6.81%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.26 (+4.73%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.26 (+7.75%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.26 (+3.06%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.26 (+3.06%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.26 (+8.65%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.26 (+12.80%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.26 (+12.15%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.26 (+13.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access